Rockwell Medical Inc 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(D)OF THE SECURITIES EXCHANGEACT OF 1934 For the quarterly period ended March31, 2026or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(D)OF THE SECURITIES EXCHANGEACT OF 1934 For the transition period fromtoCommission File Number: 000-23661ROCKWELL MEDICAL,INC.(Exact name of registrant as specified in its charter) (Former name, former address and former fiscal year, if changed since last report)Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has beensubject to such filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).☐Yes☒No Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registered: Rockwell Medical,Inc. and SubsidiariesIndex to Form10-Q PagePartI — Financial Information (unaudited)Item 1 - Unaudited Financial StatementsCondensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20253Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 20254Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2026 and20255Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31,2026 and 20256Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20257Notes to Condensed Consolidated Financial Statements8Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations14Item 3 - Quantitative and Qualitative Disclosures about Market Risk15Item 4 - Controls and Procedures15PartII — Other InformationItem 1 -Legal Proceedings15Item 1A - Risk Factors16Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds16Item 3 - Defaults Upon Senior Securities16Item 4 - Mine Safety Disclosures16Item 5 - Other Information16Item 6 -Exhibits16Signatures17 ROCKWELL MEDICAL,INC. AND SUBSIDIARIESUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(In thousands) Three Months Ended March 31,20262025Net Loss$(1,605)$(1,515)Reclassification of Realized Gain on Available-for-Sale Investments Included in Net Loss(120)(56)Unrealized Gain on Available-for-Sale Investments12262Comprehensive Loss$(1,603)$(1,509) The accompanying notes are an integral part of the condensed consolidated financial statements. ROCKWELL MEDICAL,INC. AND SUBSIDIARIESUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands) ROCKWELL MEDICAL, INC. AND SUBSIDIARIESNotes to Condensed Consolidated Financial Statements(Unaudited) 1.Description of Business Rockwell Medical, Inc. (the "Company", "Rockwell", or "Rockwell Medical") is a healthcare company that develops, manufactures,commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell is a supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients.Hemodialysis is the most commonform of end-stage kidney disease treatment and is usually performed in freestanding outpatient dialysis centers, at hospital-based outpatientcenters, skilled nursing facilities, or a patient’s home. Rockwell manufactures hemodialysis concentrates under current Good Manufacturing Practices ("cGMP") at its two facilities inMichigan and Texas, and manufactures dry acid concentrate mixers at its facility in Iowa.Rockwell delivers the majority of its hemodialysisconcentrates products and mixers to dialysis clinics throughout the United States and internationally utilizing its own delivery trucks and third-party carriers. Rockwell was incorporated in the state of Michigan in 1996 and re-